Skip to main content

Table 1 Baseline characteristics of patients treated in 52 week long-term study

From: Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study

  Most recent or current episode of bipolar I disorder
All Patients (n = 199) Depressed episode (n = 117) Non-Depressed episode (n = 82)
Demographics and clinical characteristics
 Male, n (%) 102 (51.3) 63 (53.8) 39 (47.6)
 Age years, mean (SD) 41.6 (12.0) 40.0 (10.9) 43.8 (13.1)
 Duration of bipolar I disorder, mean years (SD) 13.5 (11.1) 13.8 (10.6) 13.0 (11.7)
 With rapid cycling, n (%) 30 (15.1) 15 (12.8) 15 (18.3)
Efficacy measure at long-term study baseline
 MADRS, mean (SD) 12.4 (10.3) 16.0 (10.2) 7.3 (8.0)
 CGI-BP-S Overall, mean (SD) 2.98 (1.29) 3.10 (1.25) 2.80 (1.33)
 CGI-BP-S Depression, mean (SD) 2.51 (1.39) 3.03 (1.31) 1.77 (1.13)
 CGI-BP-S Mania, mean (SD) 1.77 (1.18) 1.23 (0.56) 2.55 (1.39)
 SDS, mean (SD)# 11.9 (8.7) 13.7 (9.03) 9.2 (7.6)
 YMRS, mean (SD) 4.7 (6.7) 2.0 (2.8) 8.7 (8.6)
 HAM-A, mean (SD) 8.3 (7.2) 10.6 (7.5) 5.0 (5.2)
Safety measure at long-term study baseline
 DIEPSS (excluding overall severity), mean (SD) 0.36 (0.78) 0.50 (0.87) 0.16 (0.60)
  1. #Number of patients: All = 181, Depressed = 109, Non-Depressed = 72
  2. CGI-BP-S Clinical Global Impression Bipolar Version Severity of illness score, DIEPSS Drug-Induced Extrapyramidal Symptoms Scale, HAM-A Hamilton Rating Scale for Anxiety total score, LUR lurasidone, MADRS Montgomery-Åsberg Depression Rating Scale, PBO placebo, SD Standard Deviation, SDS Sheehan Disability Scale, YMRS Young Mania Rating Scale